Aroa Biosurgery Limited (ASX:ARX)

Market Cap	224.27M
Revenue (ttm)	76.96M
Net Income (ttm)	-3.46M
Shares Out	345.03M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	107.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	382,350
Average Volume	182,941
Open	0.6550
Previous Close	0.6500
Day's Range	0.6400 - 0.6850
52-Week Range	0.3500 - 0.8150
Beta	0.59
RSI	56.93
Earnings Date	Nov 24, 2025

About Aroa Biosurgery

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that de...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2007
• Country: New Zealand
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ARX

Financial Performance

In 2024, Aroa Biosurgery's revenue was 84.70 million, an increase of 22.63% compared to the previous year's 69.07 million. Losses were -3.81 million, -64.12% less than in 2023.

Financial numbers in NZD